Eli Lilly and Company News Releases

Lilly and Lycia Therapeutics Enter into Strategic Collaboration to Discover and Develop Novel Lysosomal Targeting Chimera (LYTAC) Degraders

INDIANAPOLIS and SOUTH SAN FRANCISCO, Calif. , Aug. 25, 2021 /PRNewswire/ --  Eli Lilly and Company (NYSE: LLY) and Lycia Therapeutics, Inc. today announced a multi-year research collaboration and licensing agreement focused on the discovery, development and commercialization of novel targeted
favicon
investor.lilly.com
investor.lilly.com